Live Analyst Rating Changes 24956 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Toung
ARG

David Toung

Argus Research
Wall Street Analyst
★★★★☆
#330
on 13Foresight · ranked by our own returns
73%
Success Rate
+11.6%
Average Return
40 of 55 calls profitable · +0.5% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 73% of David Toung's ratings turned a profit when each position was held for 1 year — averaging +11.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

32 Buy 5 Hold 0 Sell
David's Stock Coverage 39 ratings · 2026-08-15
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
HCA
HCA Healthcare
 Aug 07, 2026 BUY Buy
+0.5% avg upside
36 analysts
$500.00
23.51% Upside
 -2.1% ·
PFE
Pfizer
 Aug 05, 2026 BUY Buy
+25.2% avg upside
45 analysts
 — +3.8% ·
BSX
Boston Scientific
 Jul 30, 2026 HOLD Strong Buy
+30.8% avg upside
38 analysts
 — +1.6% ·
DGX
Quest Diagnostics
 Jul 28, 2026 BUY Buy
-21.8% avg upside
34 analysts
$260.00
10.95% Upside
 +0.8% ·
JNJ
Johnson & Johnson
 Jul 28, 2026 BUY Strong Buy
-8.8% avg upside
39 analysts
$300.00
15.16% Upside
 -2.4% ·
DHR
Danaher
 Jul 23, 2026 BUY Strong Buy
+3.9% avg upside
45 analysts
$230.00
13.65% Upside
 -0.5% ·
UNH
UnitedHealth
 Jul 17, 2026 BUY Strong Buy
+13.5% avg upside
36 analysts
$470.00
16.92% Upside
 -6.3% ·
SYK
Stryker
 Jul 09, 2026 BUY Strong Buy
+8.8% avg upside
37 analysts
$370.00
8.99% Upside
 +4.3% ·
IART
Integra Lifesciences
 Jun 17, 2026 BUY Buy
+136.8% avg upside
21 analysts
$25.00
36.36% Upside
 +2.2% ·
LH
Labcorp Holdings
 Jun 02, 2026 BUY Strong Buy
-14.9% avg upside
37 analysts
$310.00
2.59% Downside
 +25.2% ·
IQV
IQVIA Holdings
 May 29, 2026 BUY Strong Buy
+3.3% avg upside
39 analysts
 — +29.9% ·
EW
Edwards Lifesciences
 May 21, 2026 BUY Strong Buy
+9.6% avg upside
34 analysts
 — +10.1% ·
TMO
Thermo Fisher
 Apr 30, 2026 BUY Strong Buy
+2.4% avg upside
38 analysts
$560.00
4.74% Downside
 +22.9% ·
MDT
Medtronic
 Apr 06, 2026 BUY Buy
+5.6% avg upside
38 analysts
$115.00
26.00% Upside
 +7.3% ·
BDX
Becton Dickinson
 Mar 20, 2026 BUY Buy
+7.1% avg upside
25 analysts
$180.00
1.88% Downside
 +18.9% ·
COR
Cencora
 Mar 17, 2026 BUY Buy
+2.6% avg upside
44 analysts
$400.00
27.50% Upside
 -3.0% ·
GEHC
GE Healthcare Technologies Inc
 Mar 03, 2026 BUY Strong Buy
+11.5% avg upside
22 analysts
$95.00
28.97% Upside
 -5.6% ·
SOLV
Solventum Corporation
 Dec 12, 2025 BUY Buy
+3.1% avg upside
16 analysts
 — +6.8% ·
HUM
Humana
 Dec 08, 2025 HOLD Buy
+8.3% avg upside
34 analysts
 — +51.8% ·
TECH
Bio-Techne
 Nov 20, 2025 BUY Buy
+15.2% avg upside
21 analysts
$68.00
6.12% Downside
 +23.4% ·
CRL
Charles River Labs
 Nov 17, 2025 BUY Strong Buy
-15.9% avg upside
35 analysts
$200.00
28.57% Downside
 +72.1% ·
MCK
McKesson
 Aug 20, 2025 BUY Strong Buy
-12.2% avg upside
28 analysts
$775.00
10.90% Downside
 +22.4% ·
ELV
Elevance Health
 Jul 21, 2025 HOLD Strong Buy
+12.8% avg upside
33 analysts
 — +45.3% ·
ABT
Abbott Laboratories
 Apr 21, 2025 BUY Strong Buy
+4.3% avg upside
36 analysts
$150.00
34.78% Upside
 -27.2% ·
TDOC
Teladoc
 Mar 26, 2025 HOLD Buy
+315.0% avg upside
38 analysts
 — -36.1% ·
PH
Parker Hannifin
 Aug 15, 2024 BUY Strong Buy
-8.6% avg upside
29 analysts
 — +24.8% ·
ISRG
Intuitive Surgical
 Jul 23, 2024 BUY Strong Buy
+21.7% avg upside
36 analysts
$520.00
31.81% Upside
 +10.3% ·
ZBH
Zimmer Biomet Holdings
 May 20, 2024 BUY Buy
+13.6% avg upside
38 analysts
$150.00
48.95% Upside
 -19.2% ·
LLY
Eli Lilly & Co
 Feb 07, 2024 BUY Strong Buy
-12.1% avg upside
48 analysts
$770.00
34.67% Downside
 +21.9% ·
AMGN
Amgen
 Nov 06, 2023 BUY Buy
-24.0% avg upside
57 analysts
$300.00
27.76% Downside
 +21.5% ·
MRK
Merck & Company
 Jun 06, 2023 BUY Strong Buy
-4.6% avg upside
43 analysts
$125.00
7.89% Downside
 +21.9% ·
GILD
Gilead Sciences
 Jan 28, 2022 BUY Strong Buy
-14.0% avg upside
66 analysts
$75.00
45.77% Downside
 +27.1% ·
BMY
Bristol-Myers Squibb
 Nov 01, 2021 HOLD Buy
-4.7% avg upside
42 analysts
 — +36.5% ·
ABBV
AbbVie
 Aug 05, 2021 BUY Strong Buy
-3.6% avg upside
46 analysts
$140.00
43.81% Downside
 +24.8% ·
NVS
Novartis
 Mar 10, 2021 HOLD Buy
-11.5% avg upside
24 analysts
 — +2.7% ·
CAH
Cardinal Health
 Aug 27, 2019 HOLD Strong Buy
-11.3% avg upside
29 analysts
 — +25.7% ·
BIIB
Biogen
 Feb 16, 2018 HOLD Strong Buy
+21.0% avg upside
52 analysts
 — +14.1% ·
MDRX
Veradigm
 Oct 21, 2016 BUY Buy
+199.9% avg upside
22 analysts
$19.00
287.70% Upside
 +12.8% ·
BAX
Baxter International
 Aug 15, 2016 HOLD Buy
+25.0% avg upside
23 analysts
 — +27.0% ·
🔒 34 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Toung — Frequently Asked Questions
How accurate are David Toung's stock ratings?
Based on the calls 13Foresight could measure, about 73% of David's ratings were profitable over a one-year hold, with an average return of +11.6% per rating, or +0.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is David ranked on 13Foresight?
David Toung is currently ranked #330 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on HCA, PFE, BSX, DGX, JNJ, DHR, UNH, SYK, IART, LH, IQV, EW and 27 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.